Bronchocentric granulomatosis: Difference between revisions
Jump to navigation
Jump to search
m Template |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} Nikhila Palle, M.B.B.s | ||
{{SK}} Synonym 1; Synonym 2; Synonym 3 | {{SK}} Synonym 1; Synonym 2; Synonym 3 | ||
| Line 8: | Line 8: | ||
==Historical Perspective== | ==Historical Perspective== | ||
* | *Bronchocentric granulomatosis was first discovered by Liebow, in 1973. | ||
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name]. | *In [year], [gene] mutations were first identified in the pathogenesis of [disease name]. | ||
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name]. | *In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name]. | ||
| Line 20: | Line 20: | ||
==Pathophysiology== | ==Pathophysiology== | ||
*The pathogenesis of | *The pathogenesis of bronchocentric granulomatosis is characterized by necrotizing granulomatous inflammation of the bronchi and bronchioles. | ||
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway. | *The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway. | ||
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | *On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | ||
| Line 31: | Line 31: | ||
==Differentiating [disease name] from other Diseases== | ==Differentiating [disease name] from other Diseases== | ||
* | *Bronchocentric granulomatosis must be differentiated from other diseases that cause fever, cough and chest pain, such as: | ||
:* | :*Tuberculosis | ||
:*[Differential dx2] | :*[Differential dx2] | ||
:*[Differential dx3] | :*[Differential dx3] | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* The prevalence of | * The incidence and prevalence of Bronchocentric granulomatosis is not known. | ||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop | *Patients of all age groups may develop Bronchocentric granulomatosis. | ||
*[Disease name] is more commonly observed among patients aged [age range] years old. | *[Disease name] is more commonly observed among patients aged [age range] years old. | ||
* | *Bronchocentric granulomatosis is more commonly observed among elderly patients. | ||
===Gender=== | ===Gender=== | ||
Revision as of 08:07, 16 December 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikhila Palle, M.B.B.s
Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Overview
Historical Perspective
- Bronchocentric granulomatosis was first discovered by Liebow, in 1973.
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Classification
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
Pathophysiology
- The pathogenesis of bronchocentric granulomatosis is characterized by necrotizing granulomatous inflammation of the bronchi and bronchioles.
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Causes
- [Disease name] may be caused by either [cause1], [cause2], or [cause3].
- [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
- There are no established causes for [disease name].
Differentiating [disease name] from other Diseases
- Bronchocentric granulomatosis must be differentiated from other diseases that cause fever, cough and chest pain, such as:
- Tuberculosis
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The incidence and prevalence of Bronchocentric granulomatosis is not known.
Age
- Patients of all age groups may develop Bronchocentric granulomatosis.
- [Disease name] is more commonly observed among patients aged [age range] years old.
- Bronchocentric granulomatosis is more commonly observed among elderly patients.
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with [disease name] remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- [Disease name] is usually asymptomatic.
- Symptoms of [disease name] may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with [disease name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease name].
- On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action 1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
Prevention
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].